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Introduction
Cannabis sativa has been used both therapeutically and recreationally for centuries. Δ 9 -Tetrahydrocannabinol (Δ 9 -THC) is the main psychoactive ingredient in marijuana and mediates its effects primarily through activation of two G-protein coupled receptors, CB 1 and CB 2 (Howlett, 1995) .
Identified in 1990 (Matsuda et al., 1990) , the human CB 1 receptor was found to be primarily localized in central and peripheral nervous tissue (Herkenham et al., 1990; Ishac et al., 1996) . The CB 1 receptor has been identified as a therapeutic target in a variety of disease states, including obesity (Ravinet et al., 2002) , alcohol dependence (Racz et al., 2003) , pain (Iversen and Chapman, 2002 ) and Parkinson's disease (Brotchie, 2003) . The second cannabinoid receptor, CB 2 , cloned in 1993 (Munro et al., 1993 ) is found in immune tissues, most abundantly in the spleen and leukocytes (Galiegue et al., 1995) . Selective CB 2 receptor ligands have potential therapeutic use as immune modulators for tumor suppression (Klein et al., 2003) and inflammation (Conti et al., 2002) .
Cannabinoids are defined as compounds that are either structurally similar to THC or ligands that bind to cannabinoid receptors. While THC-related compounds are referred to as classical cannabinoids (Figure 1 ), ligands structurally distinct to THC also bind to CB1 and/or CB2 receptors and are classified as nonclassical cannabinoids, aminoalkylindoles and eicosanoids. The metabolism of the classical cannabinoids (the subject of this study) is very complex. For example, approximately 100 metabolites have thus far been identified for THC. The high lipid solubility of classical cannabinoids makes them good substrates for the cytochrome P450 mixed-function oxidases. Metabolism by CYP2C9 and CYP3A4 appears to account for most of the primary THC metabolites (Watanabe et al., 2007) . For example, THC is hydroxylated at C11, at C8, and at all positions of the alkyl side-chain. C11 is the preferred hydroxylation site in man. In humans, CYP2C9 has been shown to catalyze the formation of the psychoactive 11-hydroxy metabolite of Δ 9 -THC (Bornheim et al., 1992; Watanabe et al., 1995) , and 
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CYP3A4 is responsible for hydroxylation at the 8β-position (Bornheim et al., 1992) . Following the initial hydroxylation, many of the hydroxyl groups undergo further oxidation to primarily produce carboxylic groups at C11 and C5 (alkyl side chain). In contrast to phase I metabolism, very little is known about the phase II metabolism of classical cannabinoids. Phase II metabolites appear to be mainly conjugates of the phase I metabolites with glucuronic acid, catalyzed by the activity of UDPglucuronosyltransferases (UGTs). For example, oxidation of the active metabolite Δ 9 -THC-OH leads to the inactive metabolite 11-nor-9-carboxy-Δ 9 -THC (COOH-THC). This modification of the cannabinoid also favors conjugation at the carboxyl position to form an O-esterglucuronide, which is the main metabolite found in urine (Yamamoto et al., 1987) .
Although phase II metabolism is generally thought of as a pathway to inactivate drugs, it is well known that this pathway may also result in metabolic activation. For example, morpine-6β-glucuronide (M6G) is a phase II metabolite of morphine that appears to produce equivalent, long lasting analgesia and have an improved side effect profile relative to morphine (Wittwer and Kern, 2006) . It has also been shown that acyl glucuronides of all trans retinoic acid and its derivatives exhibit significant biological activity. These compounds are less toxic than the parent compound yet retain the ability to drive cell growth, differentiation, and proliferation Gallup et al., 1987; JanickBuckner et al., 1991; Blaner and Olson, 1994) . Therefore, it is possible that phase II metabolism of cannabinoids might also produce active compounds.
To better understand this metabolic pathway, identification of the human UGTs involved in metabolism of classical cannabinoids and product characterizations are required. Therefore, the purpose of the present study was to characterize potential glucuronidated products produced by human liver microsomes and 12 human recombinant UGTs in the presence of THC derivatives, cannabinol (CBN),
-THC, (-)-Δ 9 -THC, (±)-11-hydroxy-Δ 9 -THC (11-OH-THC), and (-)-11-nor-9-This article has not been copyedited and formatted. The final version may differ from this version. 7
Materials and Methods
Materials
All chemicals used for this study were of at least reagent grade. Cannabinol (CBN), Cannabidiol (CBD), (-)-Δ 9 -THC, (±)-11-hydroxy-Δ 9 -THC, and (-)-11-nor-9-carboxy-Δ 9 -THC were purchased from Cerilliant (Round Rock, TX). [
14 C]UDP-GlcUA (325 mCi/mmol) was purchased from PerkinElmer Life Sciences (Boston, MA). Ethyl alcohol (95%) was purchased from AAPER (Shelbyville, KY). Unless otherwise specified, all other chemicals and reagents were of reagent grade and purchased from SigmaAldrich (St. Louis, MO).
Membrane fractions from baculovirus-infected insect cells expressing individual recombinant human
UGTs were prepared as previously described Kuuranne et al., 2003) . Each enzyme tested in this study is known to be active toward substrates specific for that isoform. The expression level of individual recombinant UGTs was estimated by Western blot analyses using monoclonal antibodies (Tetra-His antibodies; Qiagen, Germany) against the His-tag that all of them carry . For activity comparison between individual UGTs, the enzyme level was normalized as previously described (Kuuranne et al., 2003) .
Recombinant UGT Isoform Incubations
UGT activity was determined using were analyzed and apparent kinetic parameters were determined using Prism 4 software (GraphPad, San Diego, CA).
LC-MS/MS Analysis
Liquid chromatography-tandem mass spectrometry (LC-MS/MS) analyses for product confirmation were performed using an Agilent 1100 HPLC system (Santa Clara, CA) which was interfaced with an API 4000 triple quadrupole (MS/MS) mass spectrometer (Applied Biosystems, Foster City, CA).
Instrument operation and data acquisition was controlled through the Analyst software package (Version 
Results
Cannabinoid Glucuronidation by Human Hepatic Microsomes and Recombinant UGTs
As an initial screen for glucuronidation activity toward cannabinoids, eight human recombinant UGT1A Figure 2 ). The major product of CYP2C9 metabolism, 11-OH-THC, was specifically glucuronidated via UGT1A9 and 1A10. The highest activity towards COOH-THC was observed with UGT1A3, but HLM and UGT1A1 also showed a significant amount of activity towards this substrate. CBN, the product of THC degradation, was glucuronidated at high levels by UGT1A10 and to a lesser extent by UGT1A7, 1A9, and 2B7. Activity toward CBD was limited. HLM and UGT1A9, 2B7, and 2B17 all formed a minimal amount of a glucuronidated CBD product.
Product Confirmations/MS Spectral Interpretation
Even though some substrates did not appear to react during the initial screens (Figure 2 ), LC-MS/MS confirm that all the tested substrates served as substrates for human UGTs (Figure 3 ). Trace amounts of glucuronidated product was detected for all the substrates, but in some cases, where kinetic information could not be obtained, the physiological significance remains to be determined. MS2 chromatographs show predicted glucuronidated metabolites eluting within 2 min (Figure 3) , and the corresponding MS2
spectra have a signals consistent with predicted glucuronidated metabolites (Figure 4 and 5). The
This article has not been copyedited and formatted. The final version may differ from this version. shown) and neutral loss studies (data not shown) were designed to assess whether additional metabolites were formed but not identified during product ion scans. Neither study identified metabolites other than those observed in product ion scans (Figure 3 ). In particular, the presence of bis-and/or diglucuronidated products was not detected. MRM studies showed a small degree of in-source fragmentation.
Definite regiochemical assignments can be made for the (-)-Δ 9 -THC-(C1)-glucuronide, the CBN-(C1)-glucuronide, and the CBD-(C1)-glucuronide. C1 of (-)-Δ 9 -THC and C1 of CBN are the only active sites which is recognized by UGTs (Figure 1 ). CBD contains two hydroxyl groups at the C1 and C5 positions (Figure 1) . However, the C1 and C5 hydroxyl groups are identical due to free rotation about the bond at C6, and since no diglucuronidation was detected, there is only one possible glucuronide product. Although MS/MS data conclusively identified glucuronidated products for 11-OH-THC and COOH-THC, exact regiochemical assignments are complex because multiple reaction sites exist on these substrates and base product ions in mass spectra represent the loss of glucuronic acid.
Additional information regarding regiochemistry of glucuronidation can be determined from fragments derived from the glucuronic acid moiety (Wen et al., 2007) . Alcoholic and phenolic glucuronides are 
Steady-state Kinetics for Cannabinoid Glucuronidation by Recombinant UGTs
Based on our specific activity screen, we subjected selected UGTs to further catalytic studies to determine the respective steady-state parameters for cannabinoid glucuronidation ( Figure 5 and Table   2 ). Despite MS characterizations confirming the glucuronide production for (-)-Δ 9 -THC and CBD by UGT1A10 and UGT1A9, the sensitivity of TLC assessments was not adequate to obtain kinetic measurements. We were more successful with other enzymatic reactions. 13
Discussion
Phase I oxidation and phase II conjugation of Δ 9 -THC is generally accepted as important detoxification and excretion processes; however, the impact of these metabolic steps may be more complex than currently appreciated. This study begins characterizing specific human isozymes involved in glucuronidation of classical cannabinoids as well as characterizing products formed during these reactions. This is the first demonstration showing that several cannabinoids serve as substrates for specific human UGTs and HLM and that classical cannabinoid metabolism appears to be tissue specific.
LC-MS/MS analysis of product mixtures confirms that glucuronide conjugation does indeed occur
for all classical cannabinoids tested. Product ion scans of the desired mono-glucuronides provide MS/MS spectra for species with appropriate mass and in most cases allow for specific regiochemistry assignments.
Δ 9 -THC, CBN, and CBD are all glucuronidated at the C1 position. However, the C5 position is equivalent to C1 in CBD because there is free rotation about the chemical bond localized at the C6 position. Regiochemical assignments for 11-OH-THC and COOH-THC are not as straightforward, because these substrates contain multiple reaction sites that can give rise to different glucuronides. Reactions can occur on the carboxyl terminus of COOH-THC, on the allylic side chain of 11-OH-THC or on the phenolic group which is located in both COOH-THC and 11-OH-THC. Structure comparisons as well as substrate recognition studies suggest that glucuronidation is occurring on carboxyl terminus and on the phenolic hydroxyl group. Analyses of mass spectrum are also consistent with these conclusions (Wen et al., 2007) .
The extent of cannabinoid glucuronidation ultimately depends upon structural differences among the compounds. Despite the presence of a hydroxyl group at C1 position, 
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14 cannabinoid by hepatic UGT1A9 and the extrahepatic UGTs, UGT1A7, UGT1A8, and UGT1A10. The recognition of CBN by these UGTs likely involves π stacking with active site phenylalanines, such as those identified in binding motif for UGT1A10 (Xiong et al., 2006) . These enzyme-substrate contacts would favor binding and possibly properly orient the molecule for conjugation. The relative impact of substrate recognition is not uniform among the UGTs. For example, UGT1A9 displays the highest affinity for CBN while UGT1A10 has the lowest.
CYP2C9 oxidation of Δ 9 -THC generates 11-OH-THC, a substrate preferentially metabolized by UGT1A9 but also recognized by UGT1A10. It appears that the additional hydroxyl function group to Δ 9 -THC provides an alternate site for conjugation and/or alters the binding mode for the cannabinoid to favor UGT catalysis. Further oxidation of 11-OH-THC to COOH-THC surprisingly leads to a loss in metabolism by UGT1A9 and UGT1A10, while creating a substrate recognized by hepatic UGT1A1 and UGT1A3. These UGTs must be better suited to tolerate the introduction of a full negative charge to the cannabinoid. The resulting O-esterglucuronide of COOH-THC is the main metabolite found in urine (Yamamoto et al., 1987) , and thus these hepatic enzymes play a critical role in the metabolic clearance of cannabinoids. Taken together, phase II metabolism of cannabinoids depends on upstream processing including by enzymes such as CYP2C9 and CYP3A4 (Watanabe et al., 2007) .
This report characterizes human UGTs associated with classical cannabinoids metabolism and provides information which will be necessary to fully explore the importance of this metabolic pathway.
This study shows that UGT activity is controlled through specific P450 oxidations as well as specific enzyme-substrate mechanisms. Future studies assessing the biological activity of novel metabolites presented in this study may provide insight in developing better pain treatment options as well as help our understanding of drug dependence.
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Curve fits and kinetic constants were determined using GraphPad Prism 4 software and the resulting parameters are included in Table 2 .
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